
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing papaverine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing papaverine is listed. Products containing it are filed in the directory as unapproved drugs, in injection form. None of the listed products containing papaverine is in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Papaverine is a smooth muscle relaxant and vasodilator that compounding pharmacies prepare by prescription, most often in injectable combinations.
Papaverine is a benzylisoquinoline alkaloid, obtained from opium or made synthetically, that relaxes smooth muscle directly, especially in larger arteries, rather than through nerve signals. Unlike morphine and codeine, it has no phenanthrene group and has minimal effects on the central nervous system. The papaverine hydrochloride injections listed on DailyMed, including American Regent's, are marketed without FDA approval under the marketing category "unapproved drug other." Their labeling describes use in conditions with smooth muscle spasm, such as vascular spasm with heart attack, angina, embolism or peripheral vascular disease, and spasm of the ureter, bile ducts or gut. Prescribers have ordered compounded papaverine combined with phentolamine and alprostadil for injection (StatPearls). Compounded preparations are not FDA-approved and require a prescription.
The injection label has no boxed warning, but it states that papaverine is not indicated for treating impotence by injection into the penis, and that such injection has been reported to cause persistent priapism, a prolonged erection that needed medical and surgical treatment. Intravenous papaverine must not be used with complete heart block, and it can cause abnormal heart rhythms when conduction is impaired. Use caution with glaucoma. Stop it and call your prescriber if signs of liver hypersensitivity appear, such as yellow skin or eyes, stomach symptoms or abnormal liver tests. Dependence from abuse has been reported. The label says it should be used in pregnancy only if clearly needed. LactMed has no breastfeeding data and advises caution, with monitoring of the infant for sedation and poor feeding, especially in newborns. Flushing, sweating, headache, tiredness and dizziness can occur; talk to your prescriber or pharmacist about side effects.
Papaverine relaxes vascular, bronchial, gastrointestinal, biliary and urinary smooth muscle through a direct action unrelated to innervation; it also has a direct inotropic effect and stimulates respiration through carotid and aortic body chemoreceptors. Per the American Regent label, it localizes in fat and liver, is metabolized in the liver, is about 90% bound to plasma protein, and is excreted in urine in inactive form; estimates of its half-life vary widely. Labeled uses of the unapproved injection are the smooth muscle spasm states listed above. StatPearls on erectile dysfunction describes intracavernosal papaverine, alone or combined with phentolamine and prostaglandin E1 (TriMix) or with atropine added (QuadMix), and states that these combinations need to be prepared by a compounding pharmacy. The injection label states papaverine is not indicated for intracorporeal use for impotence. Papaverine injection should not be added to Lactated Ringer's Injection because precipitation results. Dosing is per prescriber. Monitor for priapism, cardiac rhythm in patients with conduction disease, and liver function.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth